Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1973 Nov;52(11):2697–2707. doi: 10.1172/JCI107464

Defective Ristocetin-Induced Platelet Aggregation in von Willebrand's Disease and its Correction by Factor VIII

Harvey J Weiss 1, John Rogers 1, Harvey Brand 1
PMCID: PMC302536  PMID: 4201262

Abstract

The antibiotic ristocetin, in concentrations of 1.0-1.5 mg/ml, aggregated normal platelets in citrated platelet-rich plasma by a mechanism in which the release reaction played only a minor role. Platelet aggregation by ristocetin in a concentration of 1.2 mg/ml was absent or markedly decreased in 10 patients with von Willebrand's disease. Lesser degrees of abnormality were obtained with a concentration of 1.5 mg/ml. The magnitude of the defect in ristocetin-induced platelet aggregation correlated well with the degree of abnormality of the bleeding time and the levels of antihemophilic factor (AHF, VIIIAHF) procoagulant activity. In all patients, the defect in ristocetin-induced platelet aggregation was corrected in vitro by normal plasma. Correction was also obtained with a fraction of normal cryoprecipitate that eluted in the void volume with VIIIAHF after chromatography on a gel that excludes molecules larger than 5 × 106. A similar fraction, devoid of VIIIAHF activity, obtained from patients with von Willebrand's disease had no corrective effect, but fractions obtained from patients with hemophilia were just as effective as those obtained from normal subjects. The correction activity of plasma and partially purified factor VIII was inhibited by a rabbit antibody to human factor VIII but not by a human antibody against VIIIAHF procoagulant activity. The studies provide further evidence that patients with von Willebrand's disease are deficient in a plasma factor that is necessary for normal platelet function. The activity of this factor appears to be associated with factor VIII but is unrelated to VIIIAHF procoagulant activity.

Full text

PDF
2697

Images in this article

2702Image
on p.2702

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BIEZUNSKI N., SHAFRIR E., DE VRIES A., KATCHALSKI E. The action of poly-lysine on the conversion of fibrinogen into fibrin by coagulase thrombin. Biochem J. 1955 Jan;59(1):55–58. doi: 10.1042/bj0590055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baumgartner H. R. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res. 1973 Mar;5(2):167–179. doi: 10.1016/0026-2862(73)90069-1. [DOI] [PubMed] [Google Scholar]
  3. Best G. K., Grastie M. K., McConnell R. D. Relative affinity of vancomycin and ristocetin for cell walls and uridine diphosphate-N-acetylmuramyl pentapeptide. J Bacteriol. 1970 May;102(2):476–482. doi: 10.1128/jb.102.2.476-482.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bouma B. N., Wiegerinck Y., Sixma J. J., Van Mourik J. A., Mochtar I. A. Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease. Nat New Biol. 1972 Mar 29;236(65):104–106. doi: 10.1038/newbio236104a0. [DOI] [PubMed] [Google Scholar]
  5. GANGAROSA E. J., JOHNSON T. R., RAMOS H. S. Ristocetin-induced thrombocytopenia: site and mechanism of action. Arch Intern Med. 1960 Jan;105:83–89. doi: 10.1001/archinte.1960.00270130099012. [DOI] [PubMed] [Google Scholar]
  6. Holmsen H., Weiss H. J. Further evidence for a deficient storage pool of adenine nucleotides in platelets from some patients with thrombocytopathia--"storage pool disease". Blood. 1972 Feb;39(2):197–209. [PubMed] [Google Scholar]
  7. Howard M. A., Firkin B. G. Ristocetin--a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh. 1971 Oct 31;26(2):362–369. [PubMed] [Google Scholar]
  8. Howard M. A., Sawers R. J., Firkin B. G. Ristocetin: a means of differentiating von Willebrand's disease into two groups. Blood. 1973 May;41(5):687–690. [PubMed] [Google Scholar]
  9. Hoyer L. W. Immunologic studies of antihemophilic factor (AHF, factor VIII). 3. Comparative binding properties of human and rabbit anti-AHF. Blood. 1972 Apr;39(4):481–489. [PubMed] [Google Scholar]
  10. Jerushalmy Z., Zucker M. B. Some effects of fibrinogen degradation products (FDP) on blood platelets. Thromb Diath Haemorrh. 1966 May 15;15(3):413–419. [PubMed] [Google Scholar]
  11. Kass L., Ratnoff O. D., Leon M. A. Studies on the purification of antihemophilic factor (factor 8. I. Precipitation of antihemophilic factor by concanavalin A. J Clin Invest. 1969 Feb;48(2):351–358. doi: 10.1172/JCI105991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Meyer D., Larrieu M. J. Von Willebrand factor and platelet adhesiveness. J Clin Pathol. 1970 Apr;23(3):228–231. doi: 10.1136/jcp.23.3.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mustard J. F., Packham M. A. Factors influencing platelet function: adhesion, release, and aggregation. Pharmacol Rev. 1970 Jun;22(2):97–187. [PubMed] [Google Scholar]
  14. NILSSON I. M., BLOMBACK M., VON FRANCKEN I. On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med Scand. 1957 Oct 30;159(1):35–57. doi: 10.1111/j.0954-6820.1957.tb00532.x. [DOI] [PubMed] [Google Scholar]
  15. Nieto M., Perkins H. R. The specificity of combination between ristocetins and peptides related to bacterial cell wall mucopeptide precursors. Biochem J. 1971 Oct;124(5):845–852. doi: 10.1042/bj1240845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Perkins H. A. Correction of the hemostatic defects in Von Willebrand's disease. Blood. 1967 Sep;30(3):375–380. [PubMed] [Google Scholar]
  17. Perkins H. R. Specificity of combination between mucopeptide precursors and vancomycin or ristocetin. Biochem J. 1969 Jan;111(2):195–205. doi: 10.1042/bj1110195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. SALZMAN E. W. MEASUREMENT OF PLATELET ADHESIVENESS. A SIMPLE IN VITRO TECHNIQUE DEMONSTRATING AN ABNORMALITY IN VON WILLEBRAND'S DISEASE. J Lab Clin Med. 1963 Nov;62:724–735. [PubMed] [Google Scholar]
  19. Stites D. P., Hershgold E. J., Perlman J. D., Fudenberg H. H. Factor 8 detection by hemagglutination inhibition: hemophilia A and von Willebrand's disease. Science. 1971 Jan 15;171(3967):196–197. doi: 10.1126/science.171.3967.196. [DOI] [PubMed] [Google Scholar]
  20. WROBLEWSKI F., LADUE J. S. Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med. 1955 Oct;90(1):210–213. doi: 10.3181/00379727-90-21985. [DOI] [PubMed] [Google Scholar]
  21. Weiss H. J., Aledort L. M., Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest. 1968 Sep;47(9):2169–2180. doi: 10.1172/JCI105903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Weiss H. J., Hoyer L. W., Rickles F. R., Varma A., Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest. 1973 Nov;52(11):2708–2716. doi: 10.1172/JCI107465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Weiss H. J., Kochwa S. Molecular forms of antihaemophilic globulin in plasma, cryoprecipitate and after thrombin activation. Br J Haematol. 1970 Jan;18(1):89–100. doi: 10.1111/j.1365-2141.1970.tb01421.x. [DOI] [PubMed] [Google Scholar]
  24. Weiss H. J., Kochwa S. Studies of platelet function and proteins in 3 patients with Glanzmann's thrombasthenia. J Lab Clin Med. 1968 Jan;71(1):153–165. [PubMed] [Google Scholar]
  25. Weiss H. J., Rogers J., Brand H. Properties of the platelet retention (von Willebrand) factor and its similarity to the antihemophilic factor (AHF). Blood. 1973 Jun;41(6):809–815. [PubMed] [Google Scholar]
  26. Weiss H. J., Rogers J. Correction of the platelet abnormality in von Willebrand's disease by cryoprecipitate. Am J Med. 1972 Dec;53(6):734–738. doi: 10.1016/0002-9343(72)90190-8. [DOI] [PubMed] [Google Scholar]
  27. Weiss H. J., Rogers J. Fibrinogen and platelets in the primary arrest of bleeding. Studies in two patients with congenital afibrinogenemia. N Engl J Med. 1971 Aug 12;285(7):369–374. doi: 10.1056/NEJM197108122850703. [DOI] [PubMed] [Google Scholar]
  28. Weiss H. J., Rogers J. Thrombocytopathia due to abnormalities in platelet release reaction--studies on six unrelated patients. Blood. 1972 Feb;39(2):187–196. [PubMed] [Google Scholar]
  29. Weiss H. J. Von Willebrand's disease--diagnostic criteria. Blood. 1968 Oct;32(4):668–679. [PubMed] [Google Scholar]
  30. Zimmerman T. S., Ratnoff O. D., Powell A. E. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest. 1971 Jan;50(1):244–254. doi: 10.1172/JCI106480. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES